Literature DB >> 16326988

Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome.

Elizabeth Braunlin1, Shannon Mackey-Bojack, Angela Panoskaltsis-Mortari, James M Berry, Ron T McElmurry, Megan Riddle, Li-Yan Sun, Lorne A Clarke, Jakub Tolar, Bruce R Blazar.   

Abstract

Hurler syndrome (mucopolysaccharidosis type I [MPS I]) is a uniformly lethal autosomal recessive storage disease caused by absence of the enzyme alpha-l-iduronidase (IDUA), which is involved in lysosomal degradation of sulfated glycosaminoglycans (GAGs). Cardiomyopathy and valvar insufficiency occur as GAGs accumulate in the myocardium, spongiosa of cardiac valves, and myointima of coronary arteries. Here we report the functional, biochemical, and morphologic cardiac findings in the MPS I mouse. We compare the cardiac functional and histopathological findings in the mouse to human MPS I. In MPS I mice, we have noted aortic insufficiency, increased left ventricular size, and decreased ventricular function. Aortic and mitral valves are thickened and the aortic root is dilated. However, murine MPS I is not identical to human MPS I. Myointimal proliferation of epicardial coronary arteries is unique to human MPS I, whereas dilation of aortic root appears unique to murine MPS I. Despite the differences between murine and human MPS I, the murine model provides reliable in vivo outcome parameters, such as thickened and insufficient aortic valves and depressed cardiac function that can be followed to assess the impact of therapeutic interventions in preclinical studies in Hurler syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16326988     DOI: 10.1203/01.pdr.0000190579.24054.39

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  27 in total

1.  Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation.

Authors:  Guilherme Baldo; Susan Wu; Ruth A Howe; Meera Ramamoothy; Russell H Knutsen; Jiali Fang; Robert P Mecham; Yuli Liu; Xiaobo Wu; John P Atkinson; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2011-08-24       Impact factor: 4.797

2.  Cardiac disease in mucopolysaccharidosis type I attributed to catecholaminergic and hemodynamic deficiencies.

Authors:  Nathan J Palpant; Fikru B Bedada; Brandon Peacock; Bruce R Blazar; Joseph M Metzger; Jakub Tolar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

3.  Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).

Authors:  Jakub Tolar; In-Hyun Park; Lily Xia; Chris J Lees; Brandon Peacock; Beau Webber; Ron T McElmurry; Cindy R Eide; Paul J Orchard; Michael Kyba; Mark J Osborn; Troy C Lund; John E Wagner; George Q Daley; Bruce R Blazar
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

4.  Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center.

Authors:  W P Miller; R Shanley; P Dorostkar
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

5.  Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.

Authors:  Mark J Osborn; Beau R Webber; Ronald T McElmurry; Kyle D Rudser; Anthony P DeFeo; Michael Muradian; Anna Petryk; Benedikt Hallgrimsson; Bruce R Blazar; Jakub Tolar; Elizabeth A Braunlin
Journal:  J Inherit Metab Dis       Date:  2016-10-14       Impact factor: 4.982

6.  Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Authors:  Gwen Gunn; Yanying Dai; Ming Du; Valery Belakhov; Jeyakumar Kandasamy; Trenton R Schoeb; Timor Baasov; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2013-12-17       Impact factor: 4.797

7.  General Anesthesia Management for Adult Mucopolysaccharidosis Patients Undergoing Major Spine Surgery.

Authors:  Masahiko Tsuchiya; Hidetomi Terai; Koh Mizutani; Yusuke Funai; Katsuaki Tanaka; Tokuhiro Yamada; Takashi Mori; Kiyonobu Nishikawa
Journal:  Med Princ Pract       Date:  2019-09-03       Impact factor: 1.927

8.  The mild form of mucopolysaccharidosis type I (Scheie syndrome) is associated with increased ascending aortic stiffness.

Authors:  Attila Nemes; Remco G M Timmermans; J H Paul Wilson; Osama I I Soliman; Boudewijn J Krenning; Folkert J ten Cate; Marcel L Geleijnse
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

9.  Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I.

Authors:  O I I Soliman; R G M Timmermans; A Nemes; W B Vletter; J H P Wilson; F J ten Cate; M L Geleijnse
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

10.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.